MS Bio, a regenerative medicine platform company, saw its stock price rise by over 66% on its first day of trading on the KOSDAQ. Following strong demand during institutional and retail subscription phases, the company experienced significant buying momentum on its debut.
As of 9:16 a.m. on October 22, MS Bio's shares were trading at 13,000 won, up 5,200 won (66.78%) from the initial public offering (IPO) price of 7,800 won. Shortly after the market opened, the stock began trading at more than double the IPO price.
During the public subscription for individual investors held on October 12-13, MS Bio recorded a competition rate of 1,538.51 to 1. The number of subscription applications reached 286,498, with total subscription deposits amounting to approximately 6.15 trillion won. In the preceding institutional demand forecast from September 28 to October 2, 2,269 domestic and foreign institutions participated, resulting in a competition rate of 1,096.56 to 1.
The IPO price was set at the upper end of the proposed range of 6,800 to 7,800 won. The total amount raised through the IPO was 31.2 billion won, with an expected market capitalization of about 212.2 billion won post-listing. KB Securities acted as the lead underwriter for the IPO.
Founded in 2015, MS Bio develops and produces products that aid in the reconstruction and regeneration of damaged tissues using human tissues and biomaterials. The company focuses on human tissue grafts and biomaterial-based medical devices, supplying products for soft tissue reconstruction and bone regeneration. It has expanded its product line based on technologies such as decellularization, extracellular matrix (ECM) preservation, and collagen purification and cross-linking.
The company has also shown growth in its financial performance. In 2025, MS Bio reported revenues of 23.8 billion won and an operating profit of 8.56 billion won, achieving an operating margin of approximately 36%. For the first half of 2026, revenues reached 13.9 billion won, a 26.5% increase compared to the same period last year, while operating profit rose by 21.3% to 4.5 billion won.
MS Bio plans to utilize the funds raised from the IPO for the construction of a new factory in Ochang, expansion of production facilities, establishment of overseas bases, and domestic and international clinical trials. The company aims to expand its presence in international markets, including the United States and Vietnam, and to develop and commercialize new products to target the global regenerative medicine market.
Kim Sung-po, CEO of MS Bio, stated, "MS Bio has proven its growth potential and profitability by commercializing the core technologies accumulated in the fields of human tissues and biomaterials. With this listing, we aim to strengthen the competitiveness of our existing flagship products while expanding our global business and next-generation products such as ECM skin boosters, positioning ourselves as a global regenerative medicine platform company."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.